Nov 11, 2008 · As part of this programme Genzyme opened a new Science Center in Framingham, Massachusetts on 22 September 2008. The new research facility will now serve as a centre for early-stage research using new technology in proteins, antibodies, cell therapy and gene therapy to work on diseases such as Parkinson's disease, various …

Jan 27, 2025 · HealthDay News — The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients at their Genzyme manufacturing plant in Framingham, Massachusetts. On Jan. 15, 2025, a warning letter was sent to Sanofi stating that FDA inspectors found irregularities with the ...

Jan 22, 2025 · FRAMINGHAM, MA - On January 15, 2025, the U.S. Food & Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) sent a warning to French drug manufacturer Sanofi regarding issues at it's subsidiary Genzyme Corporation facilities in Framingham, MA.

Jan 22, 2025 · Approximately 20% of bioreactor runs over 30 months were rejected due to contamination issues at Sanofi’s Framingham biologics facility, according to the US FDA.

Jan 21, 2025 · The FDA has slapped a warning letter on Sanofi’s Genzyme facility in Framingham, Massachusetts, after an inspection last summer uncovered issues around subpar manufacturing error...

Jan 25, 2018 · The newly-named Sanofi Genzyme, a subsidiary, is building a new $80 million, 72,000-square-foot bio-manufacturing facility in Framingham to expand the company’s production capacity.

Oct 15, 2019 · Framingham makes numerous products for Sanofi Genzyme, including Fabry Disease enzyme replacement therapy Fabrazyme (agalsidase beta) – production of which was moved to the site in 2012 after contamination issues at …

Oct 15, 2019 · Sanofi unveiled Tuesday a roughly 100,000-square-foot biologics manufacturing plant in Framingham, Massachusetts, touting the facility as a key cog in a broader plan to retool its production base.

Jan 22, 2025 · The FDA has issued a warning letter to Sanofi’s Genzyme facility in Framingham, Massachusetts, citing multiple manufacturing violations. Despite the regulatory scrutiny, Sanofi confirmed that there has been no disruption to the supply of drugs from the plant.

Genzyme’s manufacturing of products for the treatment of rare genetic diseases is one of Framingham’s proudest accomplishments. The company focuses strongly on rare genetic diseases such as multiple sclerosis and thyroid cancer.